CN107531796A - 识别AChE的T14肽的抗体 - Google Patents
识别AChE的T14肽的抗体 Download PDFInfo
- Publication number
- CN107531796A CN107531796A CN201680021081.0A CN201680021081A CN107531796A CN 107531796 A CN107531796 A CN 107531796A CN 201680021081 A CN201680021081 A CN 201680021081A CN 107531796 A CN107531796 A CN 107531796A
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505239.2A GB201505239D0 (en) | 2015-03-27 | 2015-03-27 | Antibody |
| GB1505239.2 | 2015-03-27 | ||
| GB1600871.6 | 2016-01-18 | ||
| GB1600871.6A GB2541477A (en) | 2015-03-27 | 2016-01-18 | Antibody |
| PCT/GB2016/050804 WO2016156803A1 (en) | 2015-03-27 | 2016-03-23 | Antibody that recognises the t14 peptide of ache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107531796A true CN107531796A (zh) | 2018-01-02 |
Family
ID=53178191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680021081.0A Pending CN107531796A (zh) | 2015-03-27 | 2016-03-23 | 识别AChE的T14肽的抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10954306B2 (https=) |
| EP (1) | EP3274371B1 (https=) |
| JP (1) | JP7327897B2 (https=) |
| KR (1) | KR102626626B1 (https=) |
| CN (1) | CN107531796A (https=) |
| AU (1) | AU2016240020B2 (https=) |
| BR (1) | BR112017020769A2 (https=) |
| CA (1) | CA2979972A1 (https=) |
| ES (1) | ES2952723T3 (https=) |
| GB (2) | GB201505239D0 (https=) |
| MX (1) | MX392158B (https=) |
| RU (1) | RU2729491C2 (https=) |
| WO (1) | WO2016156803A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001419A (zh) * | 2014-11-26 | 2017-08-01 | 神经生物有限公司 | 神经变性障碍 |
| CN108699541A (zh) * | 2016-01-28 | 2018-10-23 | 神经生物有限公司 | 癌症 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| GB202112831D0 (en) * | 2021-09-09 | 2021-10-27 | Neuro Bio Ltd | Biomarker |
| GB202113941D0 (en) | 2021-09-29 | 2021-11-10 | Neuro Bio Ltd | Skin biomarker |
| CN120187864A (zh) | 2022-09-08 | 2025-06-20 | 神经生物有限公司 | 使用t14肽诊断阿尔茨海默症的侧向流装置 |
| GB202308779D0 (en) * | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Aptamer |
| GB202308799D0 (en) | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Neurodegenerative disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035962A1 (en) * | 1996-03-22 | 1997-10-02 | Synaptica Limited | Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| WO2008135790A1 (en) * | 2007-05-04 | 2008-11-13 | Enkephala Limited | Biologically active c-terminal fragment of acetylcholinesterase |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1269201A1 (en) | 2000-03-29 | 2003-01-02 | Synaptica Limited | Alpha 7 nicotinic receptor screening assays |
| GB0028578D0 (en) * | 2000-11-23 | 2001-01-10 | Synaptica Ltd | Screening assays |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| JP5186372B2 (ja) * | 2005-08-16 | 2013-04-17 | ジェネンテック, インコーポレイテッド | 細胞/組織においてgalnac−t14発現を試験することによるapo2l/trailに対するアポトーシス感受性 |
| EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| CN101530162B (zh) * | 2008-03-10 | 2011-11-23 | 北京大北农科技集团股份有限公司 | 一种新型蛋白饲料添加剂的制备方法 |
-
2015
- 2015-03-27 GB GBGB1505239.2A patent/GB201505239D0/en not_active Ceased
-
2016
- 2016-01-18 GB GB1600871.6A patent/GB2541477A/en not_active Withdrawn
- 2016-03-23 RU RU2017133649A patent/RU2729491C2/ru active
- 2016-03-23 MX MX2017012397A patent/MX392158B/es unknown
- 2016-03-23 US US15/561,021 patent/US10954306B2/en active Active
- 2016-03-23 CA CA2979972A patent/CA2979972A1/en active Pending
- 2016-03-23 BR BR112017020769-9A patent/BR112017020769A2/en active Search and Examination
- 2016-03-23 AU AU2016240020A patent/AU2016240020B2/en not_active Ceased
- 2016-03-23 WO PCT/GB2016/050804 patent/WO2016156803A1/en not_active Ceased
- 2016-03-23 JP JP2017550514A patent/JP7327897B2/ja active Active
- 2016-03-23 EP EP16713029.3A patent/EP3274371B1/en active Active
- 2016-03-23 CN CN201680021081.0A patent/CN107531796A/zh active Pending
- 2016-03-23 ES ES16713029T patent/ES2952723T3/es active Active
- 2016-03-23 KR KR1020177027589A patent/KR102626626B1/ko active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035962A1 (en) * | 1996-03-22 | 1997-10-02 | Synaptica Limited | Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator |
| EP1270594A1 (en) * | 1996-03-22 | 2003-01-02 | Synaptica Limited | Antibodies to peptide from a soluble fragment of acetylcholinesterase |
| WO2008135790A1 (en) * | 2007-05-04 | 2008-11-13 | Enkephala Limited | Biologically active c-terminal fragment of acetylcholinesterase |
Non-Patent Citations (1)
| Title |
|---|
| MATTHEW G. COTTINGHAM等: "The Intact Human Acetylcholinesterase C-Terminal Oligomerization Domain Is R-Helical in Situ and in Isolation, but a Shorter Fragment Forms â-Sheet-Rich Amyloid Fibrils and Protofibrillar Oligomers", 《BIOCHEMISTRY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001419A (zh) * | 2014-11-26 | 2017-08-01 | 神经生物有限公司 | 神经变性障碍 |
| CN107001419B (zh) * | 2014-11-26 | 2022-02-25 | 神经生物有限公司 | 神经变性障碍 |
| CN108699541A (zh) * | 2016-01-28 | 2018-10-23 | 神经生物有限公司 | 癌症 |
| CN108699541B (zh) * | 2016-01-28 | 2025-02-11 | 神经生物有限公司 | 癌症 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201505239D0 (en) | 2015-05-13 |
| US20180051094A1 (en) | 2018-02-22 |
| US10954306B2 (en) | 2021-03-23 |
| EP3274371B1 (en) | 2023-06-07 |
| AU2016240020A1 (en) | 2017-11-02 |
| CA2979972A1 (en) | 2016-10-06 |
| ES2952723T3 (es) | 2023-11-03 |
| JP7327897B2 (ja) | 2023-08-16 |
| WO2016156803A1 (en) | 2016-10-06 |
| MX392158B (es) | 2025-03-21 |
| AU2016240020B2 (en) | 2022-02-17 |
| BR112017020769A2 (en) | 2018-06-26 |
| KR102626626B1 (ko) | 2024-01-17 |
| GB201600871D0 (en) | 2016-03-02 |
| RU2729491C2 (ru) | 2020-08-07 |
| GB2541477A (en) | 2017-02-22 |
| MX2017012397A (es) | 2018-01-26 |
| RU2017133649A3 (https=) | 2020-02-17 |
| JP2018516849A (ja) | 2018-06-28 |
| EP3274371A1 (en) | 2018-01-31 |
| RU2017133649A (ru) | 2019-04-29 |
| KR20170138414A (ko) | 2017-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7327897B2 (ja) | Acheのt14ペプチドを認識する抗体 | |
| US11739140B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| JP7029415B2 (ja) | 過リン酸化タウに特異的な抗体およびその使用方法 | |
| CA2437453C (en) | Conformationally abnormal forms of tau proteins and specific antibodies thereto | |
| KR101831459B1 (ko) | 올리고머 특이적 아밀로이드 베타 에피토프 및 항체 | |
| IL303638A (en) | Tau binding compounds | |
| WO2023143425A1 (zh) | 改善认知障碍的方法 | |
| TWI734279B (zh) | 抗α-突觸核蛋白抗體及其用途 | |
| US20230365665A1 (en) | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES | |
| US20220064271A1 (en) | Methods for treating tauopathies | |
| US20230025707A1 (en) | Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same | |
| RU2847366C1 (ru) | Профилактический или терапевтический агент для лечения деменции | |
| TW202434285A (zh) | 與異常蛋白質之聚集體形成相關之疾病的預防或治療劑 | |
| WO2021242757A1 (en) | Monocolonal antibodies against pathological tau, and methods using same | |
| WO2022060236A1 (en) | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES | |
| EA039569B1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180102 |